Lexicon Pharmaceuticals, Inc. (LXRX) Reports on Clinical Program Status and 2012 Third Quarter Results  
11/6/2012 10:31:04 AM

THE WOODLANDS, Texas, Nov. 6, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2012.

"Our positive results from a second Phase 2 study of telotristat etiprate provide further evidence of its potential to benefit patients with carcinoid syndrome," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "The initiation of a registrational Phase 3 study of telotristat etiprate in carcinoid syndrome patients represents another significant milestone in the advancement of Lexicon's clinical pipeline."